BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 6975188)

  • 1. Deoxycoformycin: neurological toxicity.
    Major PP; Agarwal RP; Kufe DW
    Cancer Chemother Pharmacol; 1981; 5(3):193-6. PubMed ID: 6975188
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurotoxicity of deoxycoformycin: effect of constant infusion on adenosine deaminase, adenosine, 2'-deoxyadenosine and monoamines in the mouse brain.
    Helland S; Broch OJ; Ueland PM
    Neuropharmacology; 1983 Jul; 22(7):915-7. PubMed ID: 6604884
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Levels of 2'-deoxycoformycin, adenosine, and deoxyadenosine in patients with acute lymphoblastic leukemia.
    Venner PM; Glazer RI; Blatt J; Sallan S; Rivera G; Holcenberg JS; Lipton J; Murphy SB; Poplack DG
    Cancer Res; 1981 Nov; 41(11 Pt 1):4508-11. PubMed ID: 6975654
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Morphological changes in leukemic lymphoblasts and normal lymphocytes treated with deoxyadenosine plus deoxycoformycin.
    Matsumoto SS; Yu AL; Yu J
    Cancer Invest; 1985; 3(3):225-33. PubMed ID: 3873981
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Toxicity and immunosuppressive activity of binary combinations of 2'-deoxycoformycin and 2'-deoxyadenosine.
    Paine RM; Weston BJ; Clink HM; Kohn J; Neville AM; McGhee KG; Harrap KR
    Cancer Treat Rep; 1981; 65(3-4):259-66. PubMed ID: 6972254
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2'-Deoxycoformycin-induced hemolysis in the mouse.
    Spremulli E; Crabtree GW; Dexter DL; Diamond I; Calabresi P
    J Natl Cancer Inst; 1982 Jun; 68(6):1011-4. PubMed ID: 6979651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S-adenosylhomocysteine catabolism and basis for acquired resistance during treatment of T-cell acute lymphoblastic leukemia with 2'-deoxycoformycin alone and in combination with 9-beta-D-arabinofuranosyladenine.
    Hershfield MS; Kredich NM; Koller CA; Mitchell BS; Kurtzberg J; Kinney TR; Falletta JM
    Cancer Res; 1983 Jul; 43(7):3451-8. PubMed ID: 6601986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Differential sensitivity of leukemic cells to growth inhibition by deoxyadenosine and deoxycoformycin.
    Tanaka M; Kimura K
    Tohoku J Exp Med; 1985 Dec; 147(4):331-41. PubMed ID: 3879563
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical pharmacology of deoxycoformycin.
    Major PP; Agarwal RP; Kufe DW
    Blood; 1981 Jul; 58(1):91-6. PubMed ID: 6263381
    [TBL] [Abstract][Full Text] [Related]  

  • 10. DNA strand breaks induced in human T-lymphocytes by the combination of deoxyadenosine and deoxycoformycin.
    Brox L; Ng A; Pollock E; Belch A
    Cancer Res; 1984 Mar; 44(3):934-7. PubMed ID: 6607110
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vivo inhibition of mouse liver methyltransferase enzymes following treatment with 2'-deoxycoformycin and 2'-deoxyadenosine.
    Renshaw J; Harrap KR
    Adv Exp Med Biol; 1986; 195 Pt B():673-5. PubMed ID: 3490129
    [No Abstract]   [Full Text] [Related]  

  • 12. Cerebrospinal fluid levels of 2'-deoxycoformycin after systemic administration in monkeys.
    Blatt J; Venner PM; Riccardi R; Cohen LF; Gangji D; Glazer RI; Poplack DG
    J Natl Cancer Inst; 1982 Mar; 68(3):391-3. PubMed ID: 6977672
    [TBL] [Abstract][Full Text] [Related]  

  • 13. 2'-deoxycoformycin. A new anticancer agent.
    Poster DS; Penta JS; Bruno S; Macdonald JS
    Cancer Clin Trials; 1981; 4(2):209-13. PubMed ID: 7018725
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of 2'-deoxycoformycin on the metabolism of purines and the survival of malignant cells in a patient with T-cell leukemia.
    Yu AL; Bakay B; Kung FH; Nyhan WL
    Cancer Res; 1981 Jul; 41(7):2677-82. PubMed ID: 6972800
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Studies on the effect of deoxyadenosine on deoxycoformycin-treated myeloid and lymphoid stem cells.
    Aye MT; Dunne JV; Yang WC
    Blood; 1982 Oct; 60(4):872-6. PubMed ID: 6981441
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biochemical basis for the differential effects of deoxycoformycin on human leukemias.
    Yu AL; Matsumoto S; Bleeker L; Alvarez A; Bakay B; Nyhan WL; Kung F
    Adv Exp Med Biol; 1984; 165 Pt B():305-8. PubMed ID: 6609536
    [No Abstract]   [Full Text] [Related]  

  • 17. Deoxycoformycin resistant mammalian cells that overproduce adenosine deaminase.
    Hoffee PA; Hunt SW
    Adv Exp Med Biol; 1984; 165 Pt A():405-10. PubMed ID: 6609531
    [No Abstract]   [Full Text] [Related]  

  • 18. Biochemical changes induced in hairy-cell leukemia following treatment with the adenosine deaminase inhibitor 2'-deoxycoformycin.
    Johnston JB; Begleiter A; Pugh L; Leith MK; Wilkins JA; Cavers DJ; Israels LG
    Cancer Res; 1986 Apr; 46(4 Pt 2):2179-84. PubMed ID: 2418965
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced cytotoxicity and inhibition of DNA damage repair in irradiated murine L5178Y lymphoblasts and human chronic lymphocytic leukemia cells treated with 2'-deoxycoformycin and deoxyadenosine in vitro.
    Begleiter A; Pugh L; Israels LG; Johnston JB
    Cancer Res; 1988 Jul; 48(14):3981-6. PubMed ID: 3260129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2'-deoxycoformycin toxicity in murine spleen lymphocytes.
    Earle MF; Glazer RI
    Mol Pharmacol; 1983 Jan; 23(1):165-70. PubMed ID: 6602939
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.